Preclinical PET and MR Evaluation of
89Zr
C57BL/6
MRI imaging
PET imaging
SCID mice
biodistribution
nanodiamonds
nanoparticles
preclinical
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
16 Dec 2022
16 Dec 2022
Historique:
received:
14
11
2022
revised:
06
12
2022
accepted:
14
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Nanodiamonds (NDs) have high potential as a drug carrier and in combination with nitrogen vacancies (NV centers) for highly sensitive MR-imaging after hyperpolarization. However, little remains known about their physiological properties in vivo. PET imaging allows further evaluation due to its quantitative properties and high sensitivity. Thus, we aimed to create a preclinical platform for PET and MR evaluation of surface-modified NDs by radiolabeling with both short- and long-lived radiotracers. Serum albumin coated NDs, functionalized with PEG groups and the chelator deferoxamine, were labeled either with zirconium-89 or gallium-68. Their biodistribution was assessed in two different mouse strains. PET scans were performed at various time points up to 7 d after i.v. injection. Anatomical correlation was provided by additional MRI in a subset of animals. PET results were validated by ex vivo quantification of the excised organs using a gamma counter. Radiolabeled NDs accumulated rapidly in the liver and spleen with a slight increase over time, while rapid washout from the blood pool was observed. Significant differences between the investigated radionuclides were only observed for the spleen (1 h). In summary, we successfully created a preclinical PET and MR imaging platform for the evaluation of the biodistribution of NDs over different time scales.
Identifiants
pubmed: 36558325
pii: nano12244471
doi: 10.3390/nano12244471
pmc: PMC9780863
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : CRC1279
Organisme : European Union
ID : Horizon 2020 grant agreement No 667192
Références
J Magn Reson. 2018 Jan;286:42-51
pubmed: 29183003
J Clin Med. 2019 Dec 29;9(1):
pubmed: 31905769
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Front Immunol. 2022 Oct 19;13:1007579
pubmed: 36341323
J Phys Chem Lett. 2014 Feb 6;5(3):597-600
pubmed: 26276615
J Mater Chem B. 2021 Oct 13;9(39):8237-8245
pubmed: 34590668
Sci Adv. 2018 Aug 31;4(8):eaat8978
pubmed: 30182060
Int J Nanomedicine. 2019 Apr 10;14:2591-2605
pubmed: 31040674
EJNMMI Res. 2014 Mar 08;4(1):15
pubmed: 24606872
Expert Opin Pharmacother. 2006 Jun;7(8):1041-53
pubmed: 16722814
J Nucl Med. 2009 Nov;50(11):1743-6
pubmed: 19837751
Adv Healthc Mater. 2015 Oct;4(14):2137-2145
pubmed: 26333024
Philos Trans A Math Phys Eng Sci. 2017 Nov 28;375(2107):
pubmed: 29038377
Cell Mol Immunol. 2016 May;13(3):267-76
pubmed: 27063467
Nanoscale. 2018 May 3;10(17):8031-8041
pubmed: 29670967
Nanomedicine. 2019 Jun;18:112-121
pubmed: 30849547
Angew Chem Int Ed Engl. 2016 Jun 1;55(23):6586-98
pubmed: 27120692
J Am Chem Soc. 2017 Jan 11;139(1):193-199
pubmed: 28009158
Theranostics. 2020 Jun 25;10(17):7921-7924
pubmed: 32685029
Front Pharmacol. 2018 Aug 14;9:802
pubmed: 30154715
Adv Drug Deliv Rev. 2017 Apr;113:157-176
pubmed: 27521055
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):471-482
pubmed: 30980411
J Control Release. 2012 Dec 10;164(2):108-14
pubmed: 22800574
Cancer Biother Radiopharm. 2020 Apr;35(3):163-166
pubmed: 32196363
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Methods Mol Med. 2001;58:205-13
pubmed: 21340860
Q J Nucl Med Mol Imaging. 2017 Jun;61(2):181-204
pubmed: 28124549
Res Immunol. 1991 May;142(4):316-20
pubmed: 1924996
Int J Nanomedicine. 2017 Apr 20;12:3281-3294
pubmed: 28458546
Nucl Med Biol. 2011 Jul;38(5):675-81
pubmed: 21718943
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
PLoS One. 2011;6(11):e27508
pubmed: 22096586
J Nanosci Nanotechnol. 2015 Feb;15(2):1070-5
pubmed: 26353614
ACS Appl Bio Mater. 2019 Jul 15;2(7):3084-3094
pubmed: 35030800
J Control Release. 2016 Sep 28;238:58-70
pubmed: 27448444
Nanoscale. 2017 Jul 13;9(27):9743-9753
pubmed: 28678239
ACS Nano. 2011 Jul 26;5(7):5552-9
pubmed: 21657210
Sci Immunol. 2019 Mar 1;4(33):
pubmed: 30824527
Mol Imaging Biol. 2008 Mar-Apr;10(2):114-20
pubmed: 18204990
Toxicol Lett. 2010 Oct 5;198(2):237-43
pubmed: 20633617
Mol Imaging Biol. 2020 Feb;22(1):73-84
pubmed: 31001765
Med Phys. 2013 Oct;40(10):102504
pubmed: 24089925
Contrast Media Mol Imaging. 2017 Dec 28;2017:6951240
pubmed: 29445321
Inorg Chem. 2020 Aug 17;59(16):11715-11727
pubmed: 32799484
Adv Drug Deliv Rev. 2020;154-155:123-141
pubmed: 32721459
Immunol Cell Biol. 2002 Feb;80(1):45-51
pubmed: 11869362
Bull Exp Biol Med. 2021 Nov;172(1):77-80
pubmed: 34797450
Neuroimage. 2012 May 1;60(4):2144-57
pubmed: 22387126
Annu Rev Immunol. 2018 Apr 26;36:247-277
pubmed: 29328785
Adv Mater. 2014 Aug 13;26(30):5119-23
pubmed: 24944166
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
Nanoscale Res Lett. 2012 Aug 23;7(1):473
pubmed: 22913534
Small. 2019 Oct;15(42):e1902992
pubmed: 31465151
ACS Omega. 2019 Feb 05;4(2):2637-2648
pubmed: 31459499
Nanomedicine. 2018 Apr 8;14(4):1429-1440
pubmed: 29641981
Nat Commun. 2015 Oct 09;6:8459
pubmed: 26450570
PLoS One. 2014 May 12;9(5):e97312
pubmed: 24819392
Nano Lett. 2019 Mar 13;19(3):2178-2185
pubmed: 30810045
Theranostics. 2014 Jan 24;4(3):290-306
pubmed: 24505237
Nanoscale. 2014 May 7;6(9):4928-35
pubmed: 24675844
Mol Imaging Biol. 2016 Jun;18(3):344-52
pubmed: 26424719
Nanoscale. 2019 Jan 23;11(4):1770-1783
pubmed: 30629069
Microcirculation. 2016 Apr;23(3):173-82
pubmed: 26237291
Int J Cancer. 1994 May 1;57(3):406-12
pubmed: 8169003